Redosable Gene-Therapy Developer Generation Bio Wins $100M Series B Financing – Genetic Engineering & Biotechnology News
Endpoints News |
Redosable Gene–Therapy Developer Generation Bio Wins $100M Series B Financing
Genetic Engineering & Biotechnology News Generation Bio, a developer of redosable gene therapies, said today it has closed on a $100 million Series B financing, with proceeds intended to advance its first two treatment candidates through Investigational New Drug (IND)-enabling studies, and … Hauling in a $100M mega-round, gene therapy startup Generation … Xconomy: Fresh Off $25M Raise, Generation Adds $100M For Next … Fidelity gets in on $100M round for gene therapy startup Generation Bio |
